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Abstract 
Age-related neurodegenerative disorders, like Alzheimer’s or Parkinson’s disease, are becoming 
a major issue to public health care. Currently, there is no effective pharmacological treatment to 
address cognitive impairment in these patients. Here, we aim to explore the role of exercise-
induced trophic factor enhancement in the prevention or delay of cognitive decline in patients with 
neurodegenerative diseases. There is a significant amount of evidence from animal and human 
studies that links neurodegenerative related cognitive deficits with changes on brain and 
peripheral trophic factor levels. Several trials with elderly individuals and patients with 
neurodegenerative diseases report exercise induced cognitive improvements and changes on 
trophic factor levels including BDNF, IGF-I, among others. Further studies with healthy aging and 
clinical populations are needed to understand how diverse exercise interventions produce 
different variations in trophic factor signaling. Genetic profiles and potential confounders 
regarding trophic factors should also be addressed in future trials. 
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1. Introduction
Elderly population is rapidly increasing all around the world. In 2010 there were a total of
524 million people aged 65 or older and by 2050 this number is estimated to triple to 1.5 billion 
[1]. As life expectancy also increases, age-related neurodegenerative disorders, such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD), are becoming more prevalent and 
represent a major issue to health care systems [2, 3]. Neurodegenerative diseases are 
characterized by progressive structural and/or functional changes in the brain, leading to several 
degrees of cognitive impairment [4-6]. In the past few decades researchers have accomplished to 
further understand age-related neurodegenerative disorders, but there is still no effective 
pharmacological treatment to address the needs of these patients. Recently, physical exercise 
has been suggested as an effective, low-cost and low-risk alternative to tackle this public health 
priority. 
It has been argued that exercise can be a preventing or disease-slowing therapeutic 
strategy for age-related neurodegenerative diseases, reducing its social and economic burden [7, 
8]. Several meta-analysis provide clear evidence that physical exercise promotes cognitive 
function in numerous domains [9, 10]  including in healthy older adults [11-14]. There is also a fair 
amount of evidence stating that physical exercise is associated with reduced incidence of 
dementia [15, 16], Mild Cognitive Impairment [MCI; 17] and lower risk of developing PD [18, 19]. 
Furthermore, there are also a significant number of systematic reviews reporting positive 
cognitive effects of exercise in AD and other kinds of dementia [20, 21], PD [22] and MCI patients 
[21, 23, 24], mainly in global cognition, executive function, attention and delayed recall.  
Recent developments in neuroimaging techniques and genetics allowed researchers to 
explore the neuroprotective mechanisms that underlie exercise induced improvements in 
neurodegenerative diseases [25, 26]. In the past few decades, researchers developed several 
animal studies in order to further understand how these neurobiological mechanisms promote 
neuroplasticity and improve cognition. Some authors argue that the differences between rodents 
and humans brain [e.g. number of neurons, protein expression] do not allow the findings on 
neurodegeneration and cognition from animal models of neurodegenerative diseases to be 
relevant to human therapy [27, 28]. However, using animal studies to understand the effects of 
exercise on the brain has been well established. Vivar and colleagues describe voluntary running 
in animal models as a critical tool to study exercise induced neural changes as it seems to mimic 
several biological brain responses that occur in humans [29]. Using this method researchers 
understood how exercise can increase the rate of neurogenesis within the dentate gyrus of the 
hippocampus [30, 31], even in older animals [32].  
In addition, the findings regarding enhanced neurogenesis have been associated with 
learning and memory improvements [33, 34]. Neuroplasticity mechanisms activated by exercise 
are clearly a complex process but animal research has consistently provided evidence of an 
exercise induced cascade of partially interdependent functional and structural changes in the 
brain, including increased dendritic spine density and angiogenesis, enhanced long-term 
potentiation as well as augmented expression of neurotransmitters and trophic factors [29, 35]. 
Nowadays it is safe to say that physical exercise is able to promote synaptogenesis and 
maintain brain volume in elderly subjects [35, 36]. Along with animal evidence, human studies 
suggest that exercise may attenuate progression of neurodegenerative processes and age-
related loss of synapses [8]. The most emergent and popular hypothesis to explain the 
relationship between psychical activity, cognition and neuroplastic mechanisms has been 
enhanced trophic factor signaling [37, 38]. Trophic factors such as brain-derived neurotrophic 
factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF) and 
insulin-like growth factor (IGF) have been identified as possible mediators of the protective and 
therapeutic effects of exercise on brain function [39, 40]. 
Several cellular and molecular mechanisms encompassing neurotrophic factors are 
important to maintain neuronal function and promote synaptic plasticity. In recent years, 
neurotrophins and their receptors have been highlighted as important regulators of adult 
neurogenesis. BDNF and its main receptors (TrkB and p75NTR) have been suggested to play a 
critical role in dendrite/spine morphogenesis, axonal initiation and progenitor 
proliferation/migration, mechanisms which support neurogenesis in the dentate gyrus of 
hippocampal formation [41]. Furthermore, BDNF has also been related to enhanced synaptic 
plasticity [42-44], late phase long-term potentiation [45], neuronal survival and differentiation  [46, 
47] and protection against neuronal death in the hippocampus [48, 49]. IGF is another trophic
factor described as a potent anabolic and mitogenic agents which activates several intracellular 
signaling cascades through Trk receptors, controlling cell proliferation, survival and differentiation 
[50]. NGF plays a role in TrkA-mediated neuroprotection and cell survival, although there is also 
evidence it’s involvement in apoptosis [51, 52]. Finally, GDNF also has a neuroprotective role as 
it activates complex interactions between several signaling cascades responsible for cell 
differentiation and proliferation as well as survival of dopaminergic and noradrenergic neurons in 
adult brain [53]. 
Thereby, it seems increasingly more likely that exercise induced upregulation of trophic 
factors can promote angiogenesis, neurogenesis and synaptogenesis, which can ultimately 
prevent age-related functional and structural neurodegeneration and the concomitant cognitive 
decline [25, 54, 55]. The purpose of this paper is to review the evidence regarding the role of 
exercise-induced trophic factor enhancement in preventing or delaying the cognitive decline of 
age-related neurodegenerative disease. Firstly, the authors will start by exploring the role of 
various trophic factors in aging and age-related neurodegenerative disorders. The authors will 
then review findings, which relate exercise, trophic factor signaling changes and cognitive 
improvements in elderly individual and patients with several neurodegenerative disorders. Finally, 
we provide several recommendations and directions by which we can further increase our 
knowledge regarding the exercise induced neuroprotection and trophic factor upregulation in 
patients with neurodegenerative diseases. 
Trophic Factors Signaling, Aging and Neurodegenerative Diseases
Trophic factor signaling has been widely explored in aging and neurodegenative
diseases. Espinet and colleagues argue that the precursor proteins of neurotrophins [pro-
neurotrophins] are implicated in the development of neurodegenerative diseases, as they play a 
role in the mechanisms related to neuron apoptosis [56]. These authors state that aging induced 
oxidative stress may enhance the expression of pro-neurotrophin forms, exacerbating its 
neurodegenerative effects. However, as we further describe throughout this section, there is a 
significant amount of evidence regarding reduced trophic signaling in patients with 
neurodegenerative diseases, with the involvement of several trophic factors including BDNF, 
NGF, GDNF and IGF-I, among others. 
2.1 Brain Derived Neurotrophic Factor (BDNF) 
BDNF is a neurotrophin widely expressed in the human brain and is crucial to regulate 
neuroprotective, neurogenesis and neuroplasticity mechanisms [57, 58]. Evidence from animal 
and human studies describe the relationship between aging, BDNF and cognitive impairment [59-
61]. Furthermore, dysfunction in BDNF signaling is related to the pathophysiologic mechanisms of 
several age-related neurodegenerative diseases [62-64]. Plasma or serum BDNF levels decline 
with age and its decrease correlates with reduced hippocampal volume and poor cognitive 
performance [65-67]. Reduced brain and peripheral expression of BDNF has also been described 
in patients with MCI [68-70]. Moreover, Forlenza and colleagues described that reduced BDNF 
levels in the cerebral spinal fluid [CSF] are associated with progression from MCI to AD [71]. 
BDNF is the most widely researched trophic factor and in recent years there has been a 
growing number of studies exploring brain and peripheral BDNF expression in AD [72-74]. Post-
mortem studies consistently found reduced BDNF mRNA or protein levels in the hippocampus of 
AD patients [75-77] among other brain regions [78-80]. Peng and colleagues found that the 
diminution of BDNF levels in AD was correlated with the degree of cognitive impairment [69]. The 
authors suggest that BDNF can be a biological marker of preclinical AD and play an important 
role in the progressive neuronal loss across the course of the disease. 
The main neurotrophin receptors, Trk receptors and p75NTR, have also been associated 
with the course of AD. Several cell survival and synaptic plasticity mechanisms are mediated by 
the interaction between neurotrophins and Trk receptors [81, 82]. Inversely, the interaction 
between neurotrophins and their precursors with p75NTR normally activates apoptotic pathways 
in peripheral neurons and glia [83, 84]. Some authors argue that the disparity between neuronal 
death and survival in AD may be caused by the upregulation of p75NTR and down regulation of 
TrK observed in these patients [85]. Furthermore, several authors reported consistently reduced 
NGF TrkA receptors in the basal forebrain and cortex of AD patients [86-88], which provides 
further evidence of impaired BDNF signaling in AD. 
Regarding peripheral blood BDNF levels, findings have been somewhat inconsistent. 
While most studies state that serum/plasma BDNF concentration declines in AD patients [89-92], 
some have found increased levels [93] or no significant changes [73]. However, several 
researches argue that BDNF levels can fluctuate accordingly to the stage or severity of the 
disease, with increase levels in early AD reflecting a compensatory neuroprotective mechanism 
to neuron distress [72, 94].  
BDNF also seems to be evolved in PD since it has a crucial role in neurotoxin induced 
degeneration of dopaminergic neurons, which display an intense decline in these patients [62]. 
Reduced BDNF mRNA and protein expression have been consistently described in the 
substancia nigra of PD patients, which is the mainly affected neuronal group in PD [62, 95, 96]. 
Moreover, serum BDNF levels have been associated with disease progression and motor 
symptoms severity [97]. BDNF may also play a role in multiple sclerosis (MS) but findings are 
somewhat inconsistent, as some authors report decreased peripheral basal levels [98], while 
others describe no significant changes [99]. Interestingly, increased brain and CSF levels of 
BDNF have also been described in MS patients [100-102]. It seems that age-related 
neurodegenerative diseases are associated with reduced BDNF function, although BDNF levels 
may vary across specific brain regions and according to symptom severity. 
2.2 Nerve Growth Factor (NGF) 
NGF is one of the oldest described neurotrophins and is responsible for protecting 
neurons from chemical stressors as well as for neuronal growth and proliferation [103]. Findings 
from animal studies suggest that NGF decreases with aging, hindering the conservation of 
cholinergic neurons and playing a role on age-dependent decline in cognitive function [104, 105]. 
The role of NGF in age-related neurodegenerative diseases has also been explored, which 
allowed to determine that NGF levels were augmented in the dentate gyrus [80], although another 
study found no brain changes in NGF expression [106]. Several authors also found no significant 
differences between peripheral NGF levels in comparison to the control group [106, 107], 
although significant increases were found in CSF levels [108]. In contrast, numerous studies have 
described increased levels of pro-NGF in AD patients [109]. Regardless of inconsistent results, a 
recent study by Ferreira and colleagues found cognitive improvements and reduced levels of 
amyloid β after NGF treatment, which can suggest that this hormone may be an important target 
in AD [110]. 
2.3 Glial Cell Line-derived Neurotrophic Factor (GDNF) 
GDNF has a significant role in the development and maintenance of spinal motor 
neurons and midbrain dopaminergic neurons [103, 111]. The neuroprotective effects of GDNF 
were explored by Pertusa and colleagues, who highlighted its role to attenuate the neuronal 
atrophy which underlies age-related cognitive deficits [112] . However, GDNF has a role in 
several neuron systems, which can explain why other authors found an increased age-related 
GDNF expression in the frontal cortex but not on the hippocampus [113]. Several authors have 
also reported reduced GDNF levels in AD and MCI patients [114, 115] in spite of others 
describing increased levels [116] or no differences in comparison to controls [107]. Interestingly, 
Straten and colleagues also found increased CSF levels of GDNF in early stage AD patients in 
contrast to reduced serum concentration, suggesting an adaptive response of the impaired brain 
[117]. As highlighted before, GDNF specifically protects the dopaminergic neurons through 
several mechanisms and its down regulation has been implicated in PD onset mechanisms [111]. 
Two cross sectional studies have found reduced levels of GDNF in patients with PD. Lower 
concentration of GDNF were found in the cerebellum and the frontal cortex of PD patients, 
although no significant changes were described in other brain regions, including the substancia 
nigra [118]. Conversely, Chauhan and colleagues reported reduced GDNF levels in the 
substancia nigra of PD patients, without any other trophic factor being affected [119].  Moreover, 
GDNF has been the main actor in several human trials, showing promising results as a potential 
therapeutic agent to treat PD through its neuroprotective and neurorestorative effects [120-122]. 
2.4 Insuline-like Growht Factor (IGF) 
IGF has also been highlighted as a crucial hormone to brain cell proliferation, survival 
and neurogenesis [123]. IGF-I levels have been associated to cognitive decline [124] and its level 
also decreases progressively as we get older [125]. Aging is associated in reduction in both 
serum IGF-I and brain density of IGF-I receptors in the hippocampus [126]. Moreover, higher 
levels of IGF-I have been associated with larger brain volumes, which points out that this factor 
can be crucial to prevent neurodegeneration [127]. Regarding AD patients, brain measures found 
reduced expression of IGF mRNA, with levels decreasing at more advanced stages of the 
disease [128]. Others authors state that IGF-I inhibition slows the progression to AD [129]. 
Changes in CSF and blood plasma levels of IGF-II have also been reported in patients with AD 
[130] and lower serum levels of IGF-I were also associated with a superior risk to develop AD 
[127]. 
The previously described trophic factors are those mainly researched when addressing 
age-related neurodegenerative diseases. Other factors such as stem cell factor (SCF), 
granulocyte-colony stimulating factor (G-CSF), and vascular endothelial growth factor (VEGF), 
among others have also been explored [103]. All the evidence clearly suggests that trophic 
signaling plays a key role in aging and neurodegenerative diseases. Establishing trophic factors 
as potential targets to prevent neurodegeneration and promote neuroprotection can be a critical 
step in order to improve treatments for age-related neurodegenerative diseases. 
3. Exercise, Trophic Factors Signaling and Cognition
In the past few years, trophic factors have been explored as the possible mediators of
exercise induced brain plasticity. Evidence from animal and human studies show that exercise 
enhances expression of several trophic factors such as BDNF, IGF-I, NGF, among others, both in 
health elderly individuals (Table 1) as well as in patients with neurodegenerative disease [Table 
2; 54, 131-134].  
Researchers have highlighted BDNF as the neurotrophin which is more susceptible to 
exercise induced changes. A recent meta-analysis by Szuhany et al. [2015] reported that both 
acute and regular exercise can increase BDNF levels in healthy subjects and clinical populations 
[135]. Several studies with healthy humans reported that physical exercise can increase plasma 
and/or serum BDNF concentration, either after acute exercise or chronic aerobic exercise [136, 
Furthermore, the review by Coelho and colleagues highlighted that both acute or chronic 
physical exercise increases peripheral BDNF concentrations in healthy elderly individuals, 
emphasizing the role of aerobic training as well as strength exercise programs [138]. There are 
also several studies with healthy elderly subjects or with participants with non-degenerative 
diagnosis [e.g. frailty, depressive symptoms] that report exercise induced BDNF upregulation 
[139-142], although two of these studies did not had any male participants. Other authors 
explored the effects of aerobic exercise on older adults and found no significant changes in 
peripheral BDNF levels after the intervention [131, 143]. However, Erickson and colleagues 
reported a crucial finding regarding BDNF induced neuroplastic changes, as participants with 
larger BDNF changes after exercise displayed higher hippocampal volume enlargement [144]. 
Several studies with MCI patients found increased peripheral BDNF levels after a 
psychical exercise intervention [145, 146]. Interestingly, Baker and colleagues described an 
enhancement of BDNF and IGF-I plasma levels in MCI patients after a 6 month aerobic exercise 
program, but only male participants displayed these changes [147]. Female participants actually 
displayed reduced BDNF levels after the intervention. In AD patients, Coelho and colleagues also 
found a significant correlation between plasma BDNF levels and the level of physical exercise 
practiced by participants [89]. 
There are also two studies reporting exercise induced peripheral BDNF levels 
enhancement in patients with PD. Zoladz and colleagues reported increases in serum BDNF 
levels after a single bout of aerobic bicycle training in PD patients [148]. A follow-up study by 
Marusiak and colleagues found increases in BDNF levels after interval exercise, which were 
correlated with improvement in motor symptoms [149]. However, both these studies did not report 
information regarding baseline group differences and did not use a control group with PD 
patients, which would be important to validate these findings.  
Regarding MS, there is evidence of exercise induced enhancement in BDNF levels after 
an acute exercise session [99] or following prolonged training programs [98, 150]. Schulz and 
colleagues reported no significant changes in BDNF after an aerobic exercise intervention, but 
the participants only completed sessions twice a week, a reduced frequency in comparison to 
previously mentioned studies [151]. 
There is also evidence linking BNDF enhancement to cognitive performance in elderly 
individuals. Anderson-Hanley and colleagues found a reduced rate of conversion to MCI after a 
cyber cycling exergame intervention, with participants also displaying a significant increase in 
BDNF levels which may have led to the reported cognitive effects [141]. Suzuki and colleagues 
also reported that elevated BDNF levels could predict cognitive improvement in older adults with 
MCI after an exercise intervention [152]. 
Exercise induced neuroprotection in the adult brain has also been related to modulation 
of IGF-I levels. Animal studies suggests that exercise promotes IGF-I uptake and neurogenesis 
by specific groups of neurons throughout the brain [153, 154]. Thereby, Carro and colleagues 
suggest that circulating IGF-I can be increased by exercise, providing a key factor to prevent or 
delay age and disease-related cognitive decline [155]. However, there is a clear need to further 
extend research in humans since results are inconsistent. Cassilhas and colleagues reported that 
resistance training increased peripheral IGF-I levels in healthy older adults [156] and Baker 
reporting exercise induced elevation of plasma IGF-I levels in men with MCI [147]. No significant 
differences were found in resting IGF-I concentration after training in MS patients [98] and some 
authors even report that aerobic exercise can lower IGF-I serum levels in healthy young and 
elderly subjects [131, 157]. 
Although BDNF and IGF-I have been further explored, researchers have also paid 
attention to other trophic factors. The neuroprotective role of NGF in aging and 
neurodegenerative diseases has also been explored, mainly in animal studies which found 
exercise induced NGF up regulation in aging rats and AD models [158, 159], although findings in 
human studies remain fairly inconsistent. Coelho and colleagues found no changes either in NGF 
and GDNF levels after a resistance training intervention in elderly women. NGF has also been 
further explored in MS patients, with findings suggesting that acute and maintained exercise may 
allow for peripheral NGF improvements [99, 150]. However, Schulz and colleagues actually found 
a trend to reduced NGF acute response after a personalized aerobic training program [151]. 
Animal studies have also reported increased VEGF peripheral levels after aerobic exercise, 
suggesting its involvement in exercise-induced neurogenesis and synaptic plasticity [160]. 
Baseline VEGF levels in older subjects are also correlated with enhanced exercise induced 
improvements in temporal cortex connectivity, which further strengthens the role of VEGF in the 
brain effects achieved by exercise [131]. 
Finally, it is also important to emphasize that the cellular source of exercise-induced 
trophic signaling changes is only partially understood. It has been argued that neurotrophic 
factors do not readily cross the blood-brain barrier (BBB), which has hindered their use as a 
therapeutic target for neurodegenerative diseases [161].  However, there is also evidence 
describing that exercise increases BBB permeability [162, 163] and that neurotrophins can cross 
it [164], which increases the likelihood of peripheral neurotrophins to cross the BBB after exercise 
in order to support neural health. For instance, BDNF can cross the BBB bi-directionally which 
allows to postulate several possible relationships between brain and plasma neurotrophic levels 
[165]. It is reasonable to assume that exercise induced blood flow to the brain enhances central 
neurotrophins expression [166, 167], as there is evidence of BDNF release in the brain during 
exercise [168]. After being produced, these neurotrophins may leave the brain in order to be 
stored in other body regions. It is also possible that increased peripheral neurotrophin levels 
induced by exercise are gradually cleared after exercise [169]. It is assumed that regardless of 
exercise intensity, peripheral BDNF concentration returns back to baseline within 15-60 minutes, 
decreasing to sub-baseline levels after that period [170], which can indicate that these molecules 
are used in the periphery or transported to the brain in order to promote neural health. 
Furthermore, we also have to account that different trophic factors are produced in 
difference areas. BDNF is mainly produced in the brain but it can also be produced by tissues in 
the periphery, mostly being released into circulation and stored in platelets [171] or produced by 
muscle cells where it is used locally [172]. On the other hand, while IGF-I is primarily produced by 
the liver [173], when released in high concentrations it can cross de BBB barrier, triggering 
increased BDNF expression in the brain [37, 174]. Trophic factors are synthetized and released in 
numerous regions, which lead researchers to struggle when trying to pinpoint whether exercise 
induced peripheral neurotrophins increase is caused by changes in peripheral or central 
mechanisms [62, 175].  
4. Expert commentary
In this article, we have reviewed the link between trophic factors and age-related
neurodegenerative diseases and how they play a key role on exercise-induced neuroprotective 
effects for these patients. There is a significant amount of clinical trials that report the 
effectiveness of physical exercise as an alternative intervention to address age-related cognitive 
impairment. Support for acknowledging exercise as a valuable intervention to the treatment of 
age-related neurodegenerative diseases comes from studies linking exercise to cognitive 
improvements and trophic signaling enhancement, which highlights trophic factors as important 
therapeutic targets to stimulate neuroprotective mechanisms [58, 176, 177]. 
Several trophic factors have been implicated in the pathogenesis and pathophysiology of 
age-related neurodegenerative diseases, but BDNF is by far the most widely studied and proven 
neurotrophin regarding exercise induced neurobiological effects. There have been few clinical 
trials exploring the role of other trophic factors, although there are some authors reporting the 
involvement of IGF-I and even NGF. Furthermore, numerous questions remain to be answered 
regarding the cellular mechanisms of exercise induced trophic signaling. Regardless, as the 
evidence regarding exercise induced brain changes in neurodegenerative diseases gradually 
increases, it seems highly unlikely that peripheral neurotrophic factors do not play a direct role in 
the underlying neuroplastic mechanisms or are at least an important indicator of enhanced 
neuroplastic activity. 
Finally, it is still hard to precisely define which exercise conditions (type, duration and 
intensity) are recommended to trigger neuroprotective effects, in spite of some reviews 
suggesting moderate intensity aerobic and resistance exercise [8, 132]. Knaepen and colleagues 
state that acute aerobic exercise is more likely to elevate BDNF concentration than acute strength 
exercise, in healthy subjects or in patients with chronic diseases [170]. Furthermore, most studies 
report a significant dose-response relationship between acute aerobic exercise intensity and 
BDNF concentration. However, there are several biases from the reported studies which hinder 
the clinician’s possibility to recommend the most effective exercise intervention, as several 
studies have reduced samples sizes, lack an appropriate control group or do not report accurately 
on data regarding exercise intensity.  Most studies found no significant differences between-
groups regarding gender and age or accounted for potential discrepancies adding these variables 
as covariates, but some studies which do report significant intervention effects do not present any 
data regarding baseline differences (Table 1 and 2). Regardless of all these reservations, it is 
safe to think about exercise-induced neuroprotective effects with two main premises. First, each 
exercise session results in enhanced neurotrophic activity that becomes gradually larger as we 
engage more regularly in physical exercise [135]. Second, as we try to accurately determine the 
right dosage to induce brain changes, it may be reasonable follow the international exercise 
recommendations for the elderly, which advises 5 weekly 30 minutes sessions of moderate 
intensity aerobic exercise [178]. 
5. Five-year view
Further understanding about the role of trophic factors on exercise-induced cognitive
improvement and neuroprotective mechanisms can be attained by developing clinical trials with 
elderly or patients with age-related neurodegenerative diseases. Researchers must be highly 
methodical when developing these trials, using matched control patients groups and clearly 
defining the characteristics of the exercise intervention they want to explore. 
However, regardless of which trophic factors account for neuroprotective mechanisms, 
researchers and clinicians must take into account several aspects that can influence the brains 
response to physical exercise. Future studies should make an effort to accurately pinpoint the 
exercise components that are responsible for cognitive outcomes and their neurobiological 
underpinnings. Neuroprotective and neuroplastic factors have a distinct role in this process, but 
there is a need to further understand the mechanisms which underlie these deficits. If animal 
studies report that specific training procedures induce different types of brains changes [40], we 
can only assume that the human brain will have distinct responses as well and there is a need to 
further understand and predict how does the human brain react to specific training procedures. 
Moreover, understanding proficiently exercise-induced neuroprotective mechanisms can also 
help to explore pharmacological alternatives that can recreate some of the effects achieved by 
exercise, allowing to develop alternative treatment strategies which target trophic factors [92, 
179-183]. 
Trophic factor levels vary widely between individual and research teams should account 
for potential confounders (e.g. age, gender, race) when designing exercise protocols and 
interpreting trial results [184]. Furthermore, methods to assess trophic factor signaling are far 
from being perfect and there is a need to develop new assessment techniques to keep track of 
brain levels of trophic factors. Genetic and/or environmental factors have a role on the response 
of the brain to physical activity and must be addressed to develop more individualized programs 
that are adapted to each patient’s aging and diagnosis [37]. 
It is clear that nowadays we are not able to perfectly describe the pathways between 
exercise, cognitive improvement and trophic factors. It is also clear that exercise has a crucial 
role on brain health during aging and neurodegenerative processes. This highlights the 
importance to develop clinical trials targeted to further understand how we can use exercise to 
prevent or treat cognitive decline associated with age-related neurodegenerative diseases, 
helping these patients to improve their daily functioning and their quality of life. 
Most of the included studies have reduced samples sizes 
6. Key-issues
- In spite of extensive research regarding age-related neurodegenerative disorders 
(Alzheimer’s disease Parkinson’s Diseases, among others), there is still no effective 
pharmacological treatments to address the needs of these patients. 
- Exercise has been clearly proven as an effective and low-cost alternative to address age 
related cognitive decline or to slow cognitive impairment associated to age-related 
neurodegenerative diseases. 
- Trophic factors such as BDNF, NGF, GDNF and IGF-I have been widely explored as 
important actors in the pathogenesis and pathophysiology of age-related 
neurodegenerative disorders. 
- There is a growing amount of evidence supporting that neurotrophic factors play a direct 
role in the underlying neuroplastic mechanisms or are at least an important indicator of 
enhanced neuroplastic activity. 
- Exercise has been postulated to enhance the expression of several trophic factors but 
BDNF is by far the most widely studied and proven neurotrophin regarding exercise 
induced neurobiological effects. 
- There is a need to develop high quality randomized controlled trials in order to strengthen 
the evidence regarding exercise-induced cognitive improvement and neuroprotective 
mechanisms in the elderly or patients with age-related neurodegenerative diseases.  
- Future work should also further explore the cellular mechanisms of exercise induced 
trophic signaling, in order to understand the role of central and peripheral mechanisms. 
- Researchers should make effort to pinpoint which exercise components (e.g. type, 
duration, frequency) are responsible for cognitive outcomes and their neurobiological 
underpinnings in age-related neurodegenerative disorders. 
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Table 1: Clinical trials regarding exercise induced trophic factors changes in healthy elderly subjects or patients with non-degenerative diseases 
Study Population Type of Exercise Sample Size 
Mean Age 
(years) 
Gender 
(% female) 
Intervention 
Length 
Session 
Frequency and 
Duration 
Intensity of Exercise 
Trophic 
Factor 
Measures 
Significant Trophic Factors Changes 
Cassilhas and 
colleagues 
(156) 
Elderly 
Resistance Training: 
Moderate Intensity (MRT) 
High Intensity (HRT) 
Stretching Exercise Control (SE) 
MRT: 19 
HRT: 20 
SE: 23 
MRT: 69 
HRT: 68.4 
SE: 67 
No female 
participants 24 weeks 
3d / week 
60 min /session 
MRT: 50% RM 
HRT: 80% RM 
Serum ↑ IGF-I levels after intervention in MRT and HRT 
Erickson and 
colleagues 
(144)* 
Elderly 
Walking Aerobic Exercise (AE) 
Stretching Exercise Control (SE) 
AE: 60 
SE: 60 
AE: 67.6 
SE: 65.5 
AE: 73% 
SE: 60% 
52 weeks 
No info on 
frequency 
40 min / session 
AE: 50% - 75% HRmax Serum 
No differences between groups after intervention 
Greater BDNF changes were associated with 
increased hippocampus volume in AE participants 
Ruscheweyh 
and colleagues 
(142)* 
Elderly 
Nordic Walking (NW) 
Gymnastics (GM) 
NW: 20 
GM: 21 
HC: 21 
NW: 60.1 
GM: 62.5 
HC: 58.1 
NW: 70% 
GM: 62% 
HC: 67% 
24 weeks 
3d / week 
50 min / session 
NW: 50 – 60% ME 
GM: 30-40% ME 
Serum ↑ BDNF associated with increased levels of physical activity (trend) 
Anderson-
Hanley and 
colleagues 
(141)* 
Elderly 
Cybercycle (CC) 
Traditional Cycling (TC) 
CC: 38 
TC: 41 
CC: 75.7 
TC:  81.6 
CC: 71% 
TC: 87% 
12 weeks 
3d / week 
45 min / session 
60% HRmax Plasma ↑  BDNF levels in CC in comparison to TC 
Voss and 
colleagues 
(131)* 
Elderly 
Walking Aerobic Exercise (AE) 
Flexing, Toning & Balance (FTB) 
AE: 30 
FTB: 35 
AE: 67.3 
FTB: 65.4 
AE: 73% 
FTB: 71% 
52 weeks 40 min / session 
AE: 50 – 75% HRmax 
FTB: 13-15 Borg Scale 
Serum 
↓ IGF-I levels after intervention in both groups 
No significant differences in BDNF and VEGF 
Baker and 
colleagues 
(143)* 
Elderly with 
Glucose 
Tolerance 
Mulimodal Aerobic Exercise 
(AE) 
Stretching Exercise Control (SE) 
AE: 19 
SE: 9 
AE: 66 
SE: 71 
AE: 53% 
SE: 90% 
24 weeks 
4d / week 
45-60 min / session 
AE: 75 - 85% HRmax 
SE: < 50% HRmax 
Plasma No significant changes in BDNF and IGF-I levels in both groups 
Laske and 
colleagues 
(139) 
Depressed 
Elderly 
Women (DE) 
Acute Aerobic Exercise 
(Incremental Treadmill Walking) 
DE: 35 
HC: 20 
DE: 61.1 
HC: 58.9 
No male 
participants Single Session 30 min / session 
Until Volitional 
Exhaustion Serum 
↑ BDNF levels only in MDD patients 
↓ BDNF after 30 min rest in both groups 
Coelho and 
colleagues 
(140)** 
Elderly 
Women 
(no frail and 
pre-frail) 
Resistance Training 
(knee flexors, extensors) 
20 71 No male participants 10 weeks 
3d / week 
60 min / session 
50% - 75% MR Plasma 
↑ Resting BDNF levels after intervention 
No significant changes in GDNF or NGF 
* Authors did not report information about baseline group differences or groups differed significantly at baseline regarding age and/or gender. However, these variables, as well as other demographic variable, were added as covariates to the analysis. 
** The authors did not report any information regarding baseline group differences and did not had any variable as a covariate. 
HC: Healthy Control Group; HRmax: Maximum Heart Rate; RM: Repetition Maximum; MR: Maximal Resistance: ME: Maximal Exertion. 
Table 2: Clinical trials regarding exercise induced trophic factors changes in patients with age-related neurodegenerative diseases 
Study Population Type of Exercise Sample Size 
Mean Age 
(years) 
Gender 
(% female) 
Intervention 
Length 
Session 
Frequency and 
Duration 
Intensity of Exercise 
Trophic 
Factor 
Measures 
Significant Trophic Factors Changes 
Baker et and 
colleagues (147) 
Mild 
Cognitive 
Impairment 
(MCI) 
Aerobic Exercise (AE) 
Stretching Exercise Control (SE) 
AE: 19 
SE: 10 
AE: 67.95 
SE: 72.6 
AE: 53% 
SE: 50% 
24 weeks 
4d / week 
45-60 min / session 
AE: 75 - 85% HRmax 
SE: < 50% HRmax 
Plasma 
↑ BDNF and IGF-I levels in male patients after AE 
↓  BDNF levels in female patients of AE 
Suzuki and 
colleagues (152) 
Mild 
Cognitive 
Impairment 
Multimodal Group Exercise - 
aerobic, strength, etc (EG) 
EG: 50 
CG: 50 
EG: 74.8 
CG: 75.8 
EG: 50% 
CG: 48% 
24 weeks 
2d / week 
90 min / session 
60% HRmax Serum Higher BDNF levels at baseline was associated with cognitive improvement 
Nascimento and 
colleagues (146) 
Mild 
Cognitive 
Impairment 
Multimodal Aerobic Exercise  
Training (MCI-T & HC-T) 
Control (MCI-C & HC) 
MCI-T: 20 
HC-T: 15 
MCI-C: 17 
HC. 15 
MCI-T: 67.3 
HC-T: 66.6 
MCI-C: 68.5 
HC: 68.1 
MCI-T: 65% 
HC-T:60% 
MCI-C: 78.6 
HC: 66.6% 
16 weeks 
3d / week 
60 min / session 
60 – 80% HRmax Plasma ↑ BDNF levels after intervention in MCI and HC training groups 
Nascimento and 
colleagues (145) 
Mild 
Cognitive 
Impairment 
Multimodal Aerobic Exercise 
(AE) 
AE: 24 
CG: 21 
AE: 67.83 
CG: 67.5 
AE: 71% 
CG: 71% 
16 weeks 
3d / week 
60 min / session 
60 – 80% HRmax Plasma 
↑ BDNF levels after intervention only in AE 
Only patients with wild-type genotype displayed 
significant improvements in BDNF 
Coelho and 
colleagues (89) 
Alzheimer 
Disease 
(AD) 
Acute Aerobic Exercise 
(Sub-maximal) 
AD: 21 
HC: 18 
AD: 76.3 
HC: 74.6 
No info Single Session No info Until 85% HRmax Plasma ↑ BDNF levels in both groups 
Zoladz and 
colleagues (148)* 
Parkinson 
Disease 
Interval Training 
(Cycling) 
12 70 42% 8 weeks 
3d / week 
60 min / session 
60-75% HRmax Serum ↑ BDNF levels after intervention 
Marusiak and 
colleagues (149)* 
Parkinson 
Disease 
(PD) 
Interval Training 
(Cycling) 
PD: 11 
HC: 11 
PD: 71 
HC: 77 
PD: 46% 
HC: 82% 
8 weeks 
3d / week 
60 min / session 
PD: Mean 68% HRmax 
HC: Mean 62% HRmax 
Serum ↑ BDNF levels only in PD patients 
Gold and 
colleagues (99) 
Multiple 
Sclerosis 
(MS) 
Acute Aerobic Exercise 
(Bycicle Ergometry) 
MS: 25 
HC: 20 
MS: 39.2 
HC: 40.5 
MS: 64% 
HC: 70% 
Single Session 30 min / session 60% VO2Max Serum 
↑ BDNF levels in both groups 
↑ NGF levels in both groups (trend) 
Schulz and 
colleagues (151) 
Multiple 
Sclerosis 
Individualized Aerobic Exercise 
(AE) 
Wait-List Control Group (CG) 
AE: 15 
CG: 13 
AE: 39 
CG: 40 
AE: 73% 
CG: 62% 
8 weeks 
2d / week 
30 min / session 
75% MW Serum 
↓ NGF levels in training group (trend) 
No significant differences in BDNF 
Castellano and 
colleagues (98)* 
Multiple 
Sclerosis Cycling Aerobic Exercise 
MS: 11 
HC: 11 
MS: 40 
HC: 40 
MS: 73% 
HC: 73% 
8 weeks 
3d / week 
30 min / session 
60% VO2Max Serum 
↑ Resting BDNF levels after 4 weeks 
No significant changes in IGF-I after training 
Bansi and 
colleagues (150) 
Multiple 
Sclerosis 
Endurance Cycling Training: 
Land Ergometer (LE) 
Aquatic Bike Training (AT) 
LE: 28 
AT: 24 
LE: 52 
AT: 50 
EG: 64% 
CG: 67% 
3 weeks 
5d / week 
30 min / session 
70% HRmax 
60% VO2Max 
Serum 
↑  BDNF after single bout of exercise in both groups 
↑   Resting BNDF levels after intervention in AT 
↑   Resting NGF after intervention in AT (trend) 
* The authors did not report any information regarding baseline group differences and did not had any variable as a covariate. 
HC: Healthy Control Group; CG: Patient Control Group; HRmax: Maximum Heart Rate; VO2Max: Maximal Oxygen Uptake; MW: Maximal Watts. 
